InfuSystem's Record Results: A Beacon of Growth in Healthcare Services

InfuSystem Holdings, Inc. (NYSE American: INFU), a leading national healthcare service provider, has announced its operational and financial results for the fourth quarter and full year 2024, marking a significant milestone in its growth trajectory. The company's dual-platform model, coupled with strategic partnerships and a diversified therapy mix, has driven impressive financial performance and positioned it for continued success.



InfuSystem's dual-platform model, comprising Patient Services and Device Solutions, has proven to be a robust growth engine. The Patient Services segment, focusing on last-mile solutions for clinic-to-home healthcare, grew by 5% in 2024, while the Device Solutions segment, supporting the Patient Services platform and leveraging strong service orientation, surged by 11%. This diversification has enabled InfuSystem to achieve record net revenues of $134.9 million in 2024, up 7% year-over-year.



The company's strategic partnerships have further enhanced its competitive position and future growth prospects. The partnership with Smith+Nephew, a global medical technology leader, has significantly expanded InfuSystem's wound care capabilities and market access. Additionally, the exclusive U.S. distribution agreement for ChemoMouthpiece, a joint venture with Sanara MedTech, addresses an unmet need for cancer patients with oral mucositis and enables InfuSystem to diversify its therapy mix and enter new markets.



InfuSystem's financial performance in 2024 reflects the strength of its dual-platform model and strategic partnerships. The company achieved record operating cash flow of $20.5 million (+82%) and adjusted EBITDA of $25.3 million (+13%). Gross margin improved to 52.2% (+2%), demonstrating the company's ability to optimize its service offerings and drive profitability.



Looking ahead, InfuSystem projects revenue growth of 8-10% in 2025, with adjusted EBITDA margins expected to exceed 2024's 18.8%. Despite planned technology upgrade investments of approximately $2.5 million, the company remains committed to driving organic growth and potential strategic acquisitions.

In conclusion, InfuSystem's record results for the fourth quarter and full year 2024 highlight the company's strong financial performance, driven by its dual-platform model, strategic partnerships, and diversified therapy mix. With a healthy balance sheet and a positive outlook for the future, InfuSystem is well-positioned to continue its growth trajectory and solidify its position as a leading national healthcare service provider.